Matches in SemOpenAlex for { <https://semopenalex.org/work/W3154226934> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W3154226934 endingPage "e692" @default.
- W3154226934 startingPage "e688" @default.
- W3154226934 abstract "Hormone receptor-positive (HR+) human epidermal growth factor receptor-2 negative (HER2-) tumors represent the most common subtype of metastatic breast cancer (MBC). International guidelines clearly state that endocrine therapy (ET) should be considered the preferred first-line therapy for these patients in the absence of very symptomatic visceral disease or evidence of endocrine resistance. Nonetheless compliance with guidelines significantly vary worldwide for many different reasons. Historically, a substantial proportion of patients with HR+ HER2- MBC have been treated with chemotherapy (CT) in first-line setting, jeopardizing patients' quality of life without a significant benefit in outcome. In 17 observational studies, including more than 63,000 patients, ET was most frequently used in first-line treatment of HR+/HER2- MBC (range, 42%-87%), nonetheless a high proportion of patients received CT (13%-66%) as initial therapy. More recently, results of clinical trials with CDK 4/6 inhibitors improved response, progression-free and overall survival in this population and are currently the standard of care. There was a trend toward increased use of ET in recent years. This review article aims to evaluate real-world data on patterns of first-line treatment of HR+ HER2- MBC with a special focus on the use of CT in this setting and the potential implications and perceived preliminary changes after the introduction of CDK 4/6 inhibitors." @default.
- W3154226934 created "2021-04-26" @default.
- W3154226934 creator A5032942551 @default.
- W3154226934 creator A5078226830 @default.
- W3154226934 creator A5082786838 @default.
- W3154226934 creator A5082903794 @default.
- W3154226934 date "2021-12-01" @default.
- W3154226934 modified "2023-09-23" @default.
- W3154226934 title "Real-world Data on First-line Systemic Therapy for Hormone Receptor-positive HER2-negative Metastatic Breast Cancer: A Trend Shift in the Era of CDK 4/6 Inhibitors" @default.
- W3154226934 cites W2090048376 @default.
- W3154226934 cites W2131106781 @default.
- W3154226934 cites W2204530481 @default.
- W3154226934 cites W2337147455 @default.
- W3154226934 cites W2342819511 @default.
- W3154226934 cites W2414550793 @default.
- W3154226934 cites W2542260290 @default.
- W3154226934 cites W2556970382 @default.
- W3154226934 cites W2753715931 @default.
- W3154226934 cites W2765167427 @default.
- W3154226934 cites W2767972188 @default.
- W3154226934 cites W2769781213 @default.
- W3154226934 cites W2790923252 @default.
- W3154226934 cites W2796824128 @default.
- W3154226934 cites W2806592404 @default.
- W3154226934 cites W2889646458 @default.
- W3154226934 cites W2890352361 @default.
- W3154226934 cites W2896416611 @default.
- W3154226934 cites W2905618274 @default.
- W3154226934 cites W2913253891 @default.
- W3154226934 cites W2964243716 @default.
- W3154226934 cites W2972049666 @default.
- W3154226934 cites W2979872375 @default.
- W3154226934 cites W2982150569 @default.
- W3154226934 cites W3006164540 @default.
- W3154226934 cites W3023933563 @default.
- W3154226934 cites W3082552926 @default.
- W3154226934 cites W3094740320 @default.
- W3154226934 doi "https://doi.org/10.1016/j.clbc.2021.04.003" @default.
- W3154226934 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33992526" @default.
- W3154226934 hasPublicationYear "2021" @default.
- W3154226934 type Work @default.
- W3154226934 sameAs 3154226934 @default.
- W3154226934 citedByCount "6" @default.
- W3154226934 countsByYear W31542269342021 @default.
- W3154226934 countsByYear W31542269342022 @default.
- W3154226934 countsByYear W31542269342023 @default.
- W3154226934 crossrefType "journal-article" @default.
- W3154226934 hasAuthorship W3154226934A5032942551 @default.
- W3154226934 hasAuthorship W3154226934A5078226830 @default.
- W3154226934 hasAuthorship W3154226934A5082786838 @default.
- W3154226934 hasAuthorship W3154226934A5082903794 @default.
- W3154226934 hasConcept C121608353 @default.
- W3154226934 hasConcept C126322002 @default.
- W3154226934 hasConcept C143998085 @default.
- W3154226934 hasConcept C2775930923 @default.
- W3154226934 hasConcept C2776694085 @default.
- W3154226934 hasConcept C2908647359 @default.
- W3154226934 hasConcept C530470458 @default.
- W3154226934 hasConcept C535046627 @default.
- W3154226934 hasConcept C71924100 @default.
- W3154226934 hasConcept C99454951 @default.
- W3154226934 hasConceptScore W3154226934C121608353 @default.
- W3154226934 hasConceptScore W3154226934C126322002 @default.
- W3154226934 hasConceptScore W3154226934C143998085 @default.
- W3154226934 hasConceptScore W3154226934C2775930923 @default.
- W3154226934 hasConceptScore W3154226934C2776694085 @default.
- W3154226934 hasConceptScore W3154226934C2908647359 @default.
- W3154226934 hasConceptScore W3154226934C530470458 @default.
- W3154226934 hasConceptScore W3154226934C535046627 @default.
- W3154226934 hasConceptScore W3154226934C71924100 @default.
- W3154226934 hasConceptScore W3154226934C99454951 @default.
- W3154226934 hasIssue "6" @default.
- W3154226934 hasLocation W31542269341 @default.
- W3154226934 hasLocation W31542269342 @default.
- W3154226934 hasOpenAccess W3154226934 @default.
- W3154226934 hasPrimaryLocation W31542269341 @default.
- W3154226934 hasRelatedWork W144521535 @default.
- W3154226934 hasRelatedWork W2092771806 @default.
- W3154226934 hasRelatedWork W2367105124 @default.
- W3154226934 hasRelatedWork W2379009234 @default.
- W3154226934 hasRelatedWork W2379151083 @default.
- W3154226934 hasRelatedWork W2388730008 @default.
- W3154226934 hasRelatedWork W2411890706 @default.
- W3154226934 hasRelatedWork W2782589310 @default.
- W3154226934 hasRelatedWork W2791179561 @default.
- W3154226934 hasRelatedWork W377899687 @default.
- W3154226934 hasVolume "21" @default.
- W3154226934 isParatext "false" @default.
- W3154226934 isRetracted "false" @default.
- W3154226934 magId "3154226934" @default.
- W3154226934 workType "article" @default.